Print pageEmail pageRSS Feeds

We are building a strong, well-run business, structured to deliver sustainable results over the long term.

Along with biotechnology leadership, the ARIAD team is focused on its commitment to deliver long-term value to investors through solid business execution. That means maintaining disciplined cost control, thoughtful capital deployment and the highest standards of corporate governance.

Webcast ImageWebcast - Replay
ARIAD Pharmaceuticals, Inc. at Goldman Sachs 36th Annual Global Healthcare Conference
06/10/15 at 11:20 a.m. PT
ARIAD Pharmaceuticals, Inc. at Goldman Sachs 36th Annual Global Healthcare Conference
Wednesday, June 10, 2015 11:20 a.m. PT  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Recent Press Releases
More >>
ARIAD Announces Long-Term Safety and Efficacy Data of Ponatinib from Phase 2 Pace Clinical Trial
ARIAD and Paladin Announce Commercial Distribution Agreement for Iclusig (Ponatinib) in Canada
Investor Downloads

Download Documentation Iclusig PACE Trial Update at EHA
Download Documentation Brigatinib Phase 1/2 Update at ASCO
Download Documentation Iclusig Phase 1 Update at ASCO
Download Documentation Brigatinib Update at ELCC: Analysis of Safety and Efficacy at Selected Phase 2 Doses
Download Documentation Brigatinib Update at ELCC: Evaluation of Brigatinib in Patients with ALK+ NSCLC and Brain Metastases
Download Documentation Investor Presentation
More >>

ARIAD Stock Price: $7.93

Stock Symbol: ARIA

Stock Exchange: NASDAQ

Stock Quote at: 07/06/15

4:00 p.m. ET
(US Dollar)
CHANGE (%) Stock is Up 0.02 (0.25%)
DAY LOW$7.58
52 WK. HIGH$9.89
Minimum 20 minute delay
Refresh quote
Data provided by Nasdaq. Minimum 15 minutes delayed.
You are now leaving this website. If you would like to continue, click Continue.